1. Introduction {#sec1}
===============

Among all thyroid cancers, medullary carcinoma (MTC) has a presentation rate around 5% and it occurs either sporadically (75% of cases) or in a hereditary pattern: familial MTC (FMTC), multiple endocrine neoplasia (MEN) type 2A and type 2B \[[@r1], [@r2]\]. The MTC rises from C-cells developing, in the beginning, as primary C-cell hyperplasia (CCH); it may evolve to early invasive medullary microcarcinoma and eventually to an invasive macroscopic form \[[@r3]\]. The tumor marker is calcitonin (32-aminoacid polypeptidic hormone), therefore in patients with nodular thyroid disease, routine calcitonin measurement has been suggested \[[@r4]-[@r7]\]. Based on these facts, it is very unlikely to find normal calcitonin levels in patients with MTC. Here we describe the case of a woman with normal serum calcitonin levels, whose thyroid was discovered, after surgery, to harbour a medullary cancer.

2. Patient {#sec2}
==========

The patient is a 45 years-old woman, who, during investigations for other diseases and in the absence of symptoms, had a neck ultrasound which incidentally revealed the presence of thyroid micronodules. Fine-needle aspiration (FNA) on thyroid prevailing nodule (middle third of the right lobe, hypoechoic with hyperechoic spots, diameters 7x8x9 mm) did not demonstrate cellular atypia.

During follow-up, the patient repeated the neck ultrasound that confirmed the presence of thyroid micronodules. Due to enlargement of the previously analyzed nodule, fine-needle aspiration was repeated (nodule n°1); FNA was also performed on another hypoechoic right nodule (nodule n°2), already present in the former ultrasound, which showed a longest diameter enlarged (10 mm).

The cytology of n°1 pointed to a Hürthle cell nodule, suspicious for follicular neoplasm, while n°2 showed cellular atypia.

The patient was, therefore, referred to surgery for right lobectomy and isthmusectomy.

The pre-surgery basal serum calcitonin (CT) was lower than 2 pg/ml (normal values \< 18.2 pg/ml). Anti-thyroid antibodies were positive (AbTG = 126 UI/ml, with normal values \<60 UI/mL, and AbTPO = 7.3 UI/ml with normal values \<50 UI/mL) and TSH and free thyroxine were within the normal range (TSH = 2.5 mUI/L with normal values 0.27-4.20 mUI/L; fT4 = 18.01 pmol/l with normal values 12-22 pmol/l).

At the same time, the patient was also diagnosed with primary hyperparathyroidism due both to high calcium (5.2 mEq/l with normal values 4.2-5.1 mEq/l) and PTH values (93 pg/ml with normal values 15-65 pg/ml); moreover neck ultrasound detected an enlarged parathyroid gland, located behind the lower pole of the right thyroid lobe. At this point a selective right low parathyroidectomy was suggested as well.

The surgeon's final decision was to perform a total thyroidectomy associated with selective right inferior parathyroidectomy.

Histological examination showed a micro-encapsulated medullary thyroid carcinoma (pT1a Nx Mx) associated with diffuse CCH and lymphocytic thyroiditis. The neoplasm showed positive staining for calcitonin and chromogranin A, while it resulted negative for thyroglobulin (Figs. **[1](#F1){ref-type="fig"}** and **[2](#F2){ref-type="fig"}**). A right parathyroid adenoma was also diagnosed. One month after surgery serum calcium and phosphate were normal and basal serum CT was \< 2 ng/ml. Carcinoembryonic antigen (CEA) levels and 24-hour urine metanephrines resulted within the normal range as well. Genetic analysis did not reveal mutation of RET proto-oncogene.

The provocative test with intravenous calcium performed after surgery did not rise CT values that remained always undetectable.

Twelve months after surgery, the patient underwent neck ultrasonography, chest and abdomen computed tomography with no evidence of residual/recurrent disease. Serum levels of CT and CEA still remained below normal thresholds.

3. Discussion and Review of Literature {#sec3}
======================================

Serum calcitonin is a specific marker for MTC useful both at the time of diagnosis and during the follow-up. It is also correlated with tumor burden and prognosis \[[@r8]-[@r10]\].

As in our case, incidentally discovered MTCs are described after thyroidectomy performed for other indications. Literature data showed that about 1-2% of thyroid nodules with indeterminate cytology, become medullary carcinomas at histological examination \[[@r11]\]. Also, in some patients operated for cytology consistent with thyroid cancer, histology revealed medullary thyroid cancer.

MTC is incidentally discovered also in patients who undergo total thyroidectomy for known differentiated thyroid cancer (DTC). Up to 3% of MTC patients have also papillary (PTC) or follicular thyroid carcinoma (FTC) on surgical pathology, (U.S. Surveillance, Epidemiology and End Results (SEER) database (1973--2002)) \[[@r12]\]. A higher prevalence of mixed MTC and PTC in thyroidectomy specimens was seen in a retrospective study of 196 consecutive cases of MTC; of these, 27 (13.8%) were found to have coincidental microscopic PTC. No association was found between the presence of microscopic PTC and overall outcome of MTC \[[@r13], [@r14]\].

The peculiarity of the present case is the absence of detectable serum calcitonin before surgery. In the literature, so far, twelve papers describing this particular condition have been published. Nine of these are case reports \[[@r15]-[@r23]\] (Table **[1](#T1){ref-type="table"}**) and the remaining four papers are reviews of thyroid surgical series where non secretory medullary thyroid cancers were found \[[@r5], [@r24]-[@r26]\]. Overall, 19 patients were described, 11 females and 6 males (gender not reported in 2 cases). The average age was 50 years old, (16--73 years), with a mean cancer size of 26 mm (range 0.5--80 mm). Of these, four patients died within 36 months from diagnosis. Final histological diagnosis was of micro-MTC in 2 patients, well differentiated MTC in 10, while the 6 remaining had poorly-differentiated MTC. In 15 cases immunohistochemical analysis was performed with positive results.

Overall, the clinical presentation and outcome of this small series are similar to those reported for MTC patients.

Such as reported in literature, some explanations for these findings have been given, such as the possibility of calcitonin assay interferences, or the "hook effect". Serum calcitonin can be measured by different immunoassay methodologies, like enzyme-linked immunosorbent assays (ELISA), radioimmunoassay (RIA), immunoradiometric assays (IRMA) and immunofluorometric assays (IFMA). The hook effect occurs when the serum antigen level is extremely high during the one-step IRMA where the signal antibodies, bound to the noncaptured antigens, are washed out during the measurement, inducing the loss of signal. To prevent the "hook effect", successive dilutions of the same sample of serum can be done \[[@r27]\]. In our case, the hook effect was excluded by performing 1:10 and 1:100 dilutions of patient's serum.

Another possible explanation for the normal serum calcitonin levels could be that the calcitonin antibodies used during immunohistochemistry (IMHC) staining, cannot recognize the calcitonin molecule due to aberrant post-translational modifications. For all the reported cases, IMHC staining was performed with the same calcitonin antibodies used for serum calcitonin assay and the tumors showed a strongly positive staining, thus excluding major abnormalities in calcitonin protein. Therefore, it seems that for unknown reasons these cells retain the ability to synthesize but not to secrete the calcitonin molecule. Theoretically, there are two potential mechanisms for impaired calcitonin secretion in our case, such reported in literature: some abnormality in the secretion of calcitonin occurs in the dedifferentiation process of the parafollicular cell towards MTC cell or there is a preneoplastic impairment in calcitonin secretion of the parafollicular cells. However, the exact mechanism remains uncertain \[[@r20]\] and we have no evidence to confirm this, although we believe that this theory may be the most plausible explanation in our case.

Conclusion
==========

Although medullary carcinoma without elevated plasma calcitonin is extremely rare, we decided to describe the present case in order to emphasize that normal or low levels of calcitonin, especially when a thyroid neoplasm is suspected, do not entirely exclude this diagnosis.
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Medullary Thyroid Cancer and Normal pre-surgery Serum Calcitonin, Case Report.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Sex/Age**   **Tumor Size**   **TNM Stage**   **RET**\       **Familial History**   **Immunohistochemistry**\   **References**                  
                                                 **Mutation**                          **CT CEA SPH CGA TG**                                       
  ------------- ---------------- --------------- -------------- ---------------------- --------------------------- ---------------- ---- ---- ---- -----------------
  F/39          2,6 cm           II              \-             \-                     \+                          NA               NA   \+   NA   2014 \[[@r20]\]

  F/16          3 cm             II              \-             \-                     \+                          \+               NA   \+   NA   2011 \[[@r21]\]

  F/43          4,5 cm           III             \-             \-                     \+                          \+               \-   \+   \-   2008 \[[@r22]\]

  M/44          1.7 cm           III             \-             \-                     \+                          \+               \+   \+   \-   2008 \[[@r19]\]

  M/48          5 cm             IV              NA             \-                     \+                          \+               \+   \+   \-   2007 \[[@r17]\]

  F/73          NA               IV              NA             \-                     \+                          \+               NA   NA   NA   2006 \[[@r14]\]

  F/50          2 cm             II              \-             \-                     \+                          \+               NA   \+   \-   2004 \[[@r16]\]

  F/30          4.5 cm           III             \-             \-                     \+                          \+               \+   \-   \-   2000 \[[@r18]\]

  F/65          NA               IV              NA             \-                     \+                          NA               NA   NA   NA   1997 \[[@r15]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

CT: calcitonin; CEA: carcinoembryonic antigen; SPH: synaptophysin; CGA: chromogranin A; TG: thyroglobulin.
